Annual FCF:
-$978.00M-$4.26B(-129.83%)Summary
- As of April 2, 2025, VRTX annual free cash flow is -$978.00 million, with the most recent change of -$4.26 billion (-129.83%) on December 31, 2024.
- During the last 3 years, VRTX annual FCF has fallen by -$3.39 billion (-140.61%).
- VRTX annual FCF is now -124.92% below its all-time high of $3.93 billion, reached on December 31, 2022.
Performance
VRTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF:
$492.00M-$810.10M(-62.21%)Summary
- As of April 2, 2025, VRTX quarterly free cash flow is $492.00 million, with the most recent change of -$810.10 million (-62.21%) on December 31, 2024.
- Over the past year, VRTX quarterly FCF has stayed the same.
- VRTX quarterly FCF is now -62.21% below its all-time high of $1.30 billion, reached on September 30, 2024.
Performance
VRTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF:
-$978.00M+$373.50M(+27.64%)Summary
- As of April 2, 2025, VRTX TTM free cash flow is -$978.00 million, with the most recent change of +$373.50 million (+27.64%) on December 31, 2024.
- Over the past year, VRTX TTM FCF has stayed the same.
- VRTX TTM FCF is now -123.26% below its all-time high of $4.21 billion, reached on September 30, 2023.
Performance
VRTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
VRTX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -129.8% | 0.0% | 0.0% |
| 3 y3 years | -140.6% | -45.4% | -125.7% |
| 5 y5 years | -165.5% | -45.4% | -125.7% |
VRTX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -124.9% | at low | -62.2% | +112.8% | -123.3% | +31.4% |
| 5 y | 5-year | -124.9% | at low | -62.2% | +112.8% | -123.3% | +31.4% |
| alltime | all time | -124.9% | at low | -62.2% | +112.8% | -123.3% | +31.4% |
Vertex Pharmaceuticals Incorporated Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$978.00M(-129.8%) | $492.00M(-62.2%) | -$978.00M(-27.6%) |
| Sep 2024 | - | $1.30B(-134.0%) | -$1.35B(-5.2%) |
| Jun 2024 | - | -$3.83B(-462.0%) | -$1.43B(-141.0%) |
| Mar 2024 | - | $1.06B(+793.0%) | $3.48B(+6.1%) |
| Dec 2023 | $3.28B(-16.5%) | $118.50M(-90.3%) | $3.28B(-22.0%) |
| Sep 2023 | - | $1.23B(+14.2%) | $4.21B(+8.4%) |
| Jun 2023 | - | $1.07B(+25.3%) | $3.88B(-0.3%) |
| Mar 2023 | - | $857.80M(-17.9%) | $3.89B(-0.9%) |
| Dec 2022 | $3.93B(+63.0%) | $1.04B(+15.9%) | $3.93B(+2.9%) |
| Sep 2022 | - | $901.30M(-17.0%) | $3.81B(+0.7%) |
| Jun 2022 | - | $1.09B(+21.7%) | $3.79B(+54.5%) |
| Mar 2022 | - | $892.60M(-4.4%) | $2.45B(+1.8%) |
| Dec 2021 | $2.41B(-19.5%) | $933.20M(+6.7%) | $2.41B(+25.5%) |
| Sep 2021 | - | $874.80M(-450.5%) | $1.92B(+8.0%) |
| Jun 2021 | - | -$249.60M(-129.4%) | $1.78B(-41.7%) |
| Mar 2021 | - | $850.10M(+91.5%) | $3.05B(+1.8%) |
| Dec 2020 | $2.99B(+100.4%) | $443.84M(-39.4%) | $2.99B(+0.5%) |
| Sep 2020 | - | $732.95M(-28.2%) | $2.98B(+16.5%) |
| Jun 2020 | - | $1.02B(+28.2%) | $2.56B(+28.9%) |
| Mar 2020 | - | $796.25M(+85.5%) | $1.98B(+32.8%) |
| Dec 2019 | $1.49B(+27.2%) | $429.27M(+38.3%) | $1.49B(+9.6%) |
| Sep 2019 | - | $310.50M(-30.6%) | $1.36B(-3.5%) |
| Jun 2019 | - | $447.39M(+45.9%) | $1.41B(+12.3%) |
| Mar 2019 | - | $306.74M(+2.6%) | $1.26B(+7.1%) |
| Dec 2018 | $1.17B(+100.6%) | $298.93M(-17.1%) | $1.17B(+10.8%) |
| Sep 2018 | - | $360.44M(+23.4%) | $1.06B(+55.5%) |
| Jun 2018 | - | $292.09M(+30.8%) | $682.12M(+23.1%) |
| Mar 2018 | - | $223.38M(+21.1%) | $554.31M(-5.3%) |
| Dec 2017 | $585.52M(+226.1%) | $184.53M(-1132.4%) | $585.52M(+10.3%) |
| Sep 2017 | - | -$17.87M(-110.9%) | $530.93M(-11.6%) |
| Jun 2017 | - | $164.28M(-35.5%) | $600.58M(+30.2%) |
| Mar 2017 | - | $254.59M(+95.9%) | $461.24M(+156.9%) |
| Dec 2016 | $179.54M(-143.7%) | $129.94M(+151.0%) | $179.54M(+171.1%) |
| Sep 2016 | - | $51.77M(+107.6%) | $66.22M(-217.4%) |
| Jun 2016 | - | $24.94M(-192.0%) | -$56.42M(-72.5%) |
| Mar 2016 | - | -$27.11M(-263.2%) | -$205.05M(-50.1%) |
| Dec 2015 | -$410.73M(-34.2%) | $16.62M(-123.4%) | -$410.73M(-34.2%) |
| Sep 2015 | - | -$70.87M(-42.7%) | -$623.81M(-4.0%) |
| Jun 2015 | - | -$123.69M(-46.9%) | -$649.88M(-2.4%) |
| Mar 2015 | - | -$232.79M(+18.5%) | -$665.82M(+6.6%) |
| Dec 2014 | -$624.31M(+457.1%) | -$196.46M(+102.6%) | -$624.31M(+47.7%) |
| Sep 2014 | - | -$96.94M(-30.6%) | -$422.57M(+18.1%) |
| Jun 2014 | - | -$139.62M(-27.0%) | -$357.86M(+62.0%) |
| Mar 2014 | - | -$191.29M(-3717.4%) | -$220.96M(+97.2%) |
| Dec 2013 | -$112.06M(-157.0%) | $5.29M(-116.4%) | -$112.06M(+6.9%) |
| Sep 2013 | - | -$32.23M(+1081.6%) | -$104.83M(-976.2%) |
| Jun 2013 | - | -$2.73M(-96.7%) | $11.96M(-89.8%) |
| Mar 2013 | - | -$82.39M(-758.4%) | $117.56M(-40.2%) |
| Dec 2012 | $196.70M(+80.2%) | $12.51M(-85.2%) | $196.70M(-73.4%) |
| Sep 2012 | - | $84.56M(-17.8%) | $738.52M(+7.5%) |
| Jun 2012 | - | $102.86M(-3275.7%) | $686.87M(+131.0%) |
| Mar 2012 | - | -$3.24M(-100.6%) | $297.38M(+172.5%) |
| Dec 2011 | $109.14M(-116.2%) | $554.33M(+1584.4%) | $109.14M(-117.4%) |
| Sep 2011 | - | $32.91M(-111.5%) | -$625.73M(-24.9%) |
| Jun 2011 | - | -$286.63M(+49.7%) | -$833.46M(+25.3%) |
| Mar 2011 | - | -$191.48M(+6.1%) | -$665.40M(-1.2%) |
| Dec 2010 | -$673.50M(+49.3%) | -$180.53M(+3.3%) | -$673.50M(+11.7%) |
| Sep 2010 | - | -$174.82M(+47.4%) | -$602.87M(+32.7%) |
| Jun 2010 | - | -$118.57M(-40.6%) | -$454.44M(-0.9%) |
| Mar 2010 | - | -$199.57M(+81.6%) | -$458.52M(+1.6%) |
| Dec 2009 | -$451.08M(+74.4%) | -$109.91M(+316.5%) | -$451.08M(+1.4%) |
| Sep 2009 | - | -$26.39M(-78.5%) | -$445.01M(-20.0%) |
| Jun 2009 | - | -$122.65M(-36.2%) | -$556.61M(+63.8%) |
| Mar 2009 | - | -$192.14M(+85.0%) | -$339.77M(+31.4%) |
| Dec 2008 | -$258.66M | -$103.84M(-24.7%) | -$258.66M(+21.6%) |
| Sep 2008 | - | -$137.99M(-246.5%) | -$212.72M(+45.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2008 | - | $94.19M(-184.8%) | -$146.30M(-54.6%) |
| Mar 2008 | - | -$111.03M(+91.8%) | -$321.98M(+13.0%) |
| Dec 2007 | -$284.89M(+419.0%) | -$57.89M(-19.1%) | -$284.89M(+19.5%) |
| Sep 2007 | - | -$71.57M(-12.2%) | -$238.47M(+229.4%) |
| Jun 2007 | - | -$81.49M(+10.2%) | -$72.40M(+19.3%) |
| Mar 2007 | - | -$73.94M(+544.4%) | -$60.67M(+10.5%) |
| Dec 2006 | -$54.89M(-71.0%) | -$11.47M(-112.1%) | -$54.89M(-1.2%) |
| Sep 2006 | - | $94.50M(-235.5%) | -$55.56M(-73.6%) |
| Jun 2006 | - | -$69.76M(+2.3%) | -$210.81M(+5.9%) |
| Mar 2006 | - | -$68.16M(+461.2%) | -$199.10M(+5.3%) |
| Dec 2005 | -$189.01M(+22.2%) | -$12.14M(-80.0%) | -$189.01M(-7.5%) |
| Sep 2005 | - | -$60.74M(+4.6%) | -$204.31M(+8.1%) |
| Jun 2005 | - | -$58.05M(-0.0%) | -$189.07M(+19.7%) |
| Mar 2005 | - | -$58.07M(+111.6%) | -$157.98M(+2.1%) |
| Dec 2004 | -$154.66M(-16.4%) | -$27.45M(-39.7%) | -$154.66M(-3.4%) |
| Sep 2004 | - | -$45.51M(+68.8%) | -$160.03M(-0.9%) |
| Jun 2004 | - | -$26.95M(-50.8%) | -$161.41M(-11.7%) |
| Mar 2004 | - | -$54.75M(+66.8%) | -$182.71M(-1.2%) |
| Dec 2003 | -$184.97M(+56.2%) | -$32.82M(-30.0%) | -$184.97M(+6.4%) |
| Sep 2003 | - | -$46.88M(-2.9%) | -$173.85M(+10.3%) |
| Jun 2003 | - | -$48.26M(-15.3%) | -$157.65M(+16.5%) |
| Mar 2003 | - | -$57.01M(+162.8%) | -$135.33M(+14.3%) |
| Dec 2002 | -$118.41M(+94.3%) | -$21.69M(-29.3%) | -$118.41M(+78.9%) |
| Sep 2002 | - | -$30.68M(+18.3%) | -$66.19M(-30.7%) |
| Jun 2002 | - | -$25.94M(-35.3%) | -$95.51M(+15.8%) |
| Mar 2002 | - | -$40.09M(-231.3%) | -$82.47M(+35.3%) |
| Dec 2001 | -$60.95M(+98.3%) | $30.53M(-150.9%) | -$60.95M(-46.2%) |
| Sep 2001 | - | -$60.00M(+365.0%) | -$113.29M(+73.7%) |
| Jun 2001 | - | -$12.90M(-30.5%) | -$65.21M(+109.6%) |
| Mar 2001 | - | -$18.57M(-14.9%) | -$31.11M(+1.2%) |
| Dec 2000 | -$30.74M(-36.0%) | -$21.82M(+83.1%) | -$30.74M(+1168.7%) |
| Sep 2000 | - | -$11.92M(-156.2%) | -$2.42M(-75.1%) |
| Jun 2000 | - | $21.20M(-216.5%) | -$9.74M(-80.0%) |
| Mar 2000 | - | -$18.20M(-380.0%) | -$48.80M(+1.7%) |
| Dec 1999 | -$48.00M(+23.1%) | $6.50M(-133.8%) | -$48.00M(-28.9%) |
| Sep 1999 | - | -$19.23M(+7.7%) | -$67.50M(+39.3%) |
| Jun 1999 | - | -$17.87M(+2.7%) | -$48.47M(+15.4%) |
| Mar 1999 | - | -$17.40M(+33.8%) | -$42.00M(+7.7%) |
| Dec 1998 | -$39.00M(+153.2%) | -$13.00M(+6400.0%) | -$39.00M(+24.2%) |
| Sep 1998 | - | -$200.00K(-98.2%) | -$31.40M(-10.5%) |
| Jun 1998 | - | -$11.40M(-20.8%) | -$35.10M(+41.5%) |
| Mar 1998 | - | -$14.40M(+166.7%) | -$24.80M(+61.0%) |
| Dec 1997 | -$15.40M(-65.2%) | -$5.40M(+38.5%) | -$15.40M(+1.3%) |
| Sep 1997 | - | -$3.90M(+254.5%) | -$15.20M(-19.1%) |
| Jun 1997 | - | -$1.10M(-78.0%) | -$18.80M(-53.5%) |
| Mar 1997 | - | -$5.00M(-3.8%) | -$40.40M(-8.8%) |
| Dec 1996 | -$44.30M(+107.0%) | -$5.20M(-30.7%) | -$44.30M(+4.2%) |
| Sep 1996 | - | -$7.50M(-67.0%) | -$42.50M(+6.0%) |
| Jun 1996 | - | -$22.70M(+155.1%) | -$40.10M(+61.7%) |
| Mar 1996 | - | -$8.90M(+161.8%) | -$24.80M(+15.9%) |
| Dec 1995 | -$21.40M(+28.9%) | -$3.40M(-33.3%) | -$21.40M(-10.1%) |
| Sep 1995 | - | -$5.10M(-31.1%) | -$23.80M(+10.2%) |
| Jun 1995 | - | -$7.40M(+34.5%) | -$21.60M(+24.9%) |
| Mar 1995 | - | -$5.50M(-5.2%) | -$17.30M(+4.2%) |
| Dec 1994 | -$16.60M(-344.1%) | -$5.80M(+100.0%) | -$16.60M(+1975.0%) |
| Sep 1994 | - | -$2.90M(-6.5%) | -$800.00K(-144.4%) |
| Jun 1994 | - | -$3.10M(-35.4%) | $1.80M(-64.7%) |
| Mar 1994 | - | -$4.80M(-148.0%) | $5.10M(-25.0%) |
| Dec 1993 | $6.80M(-200.0%) | $10.00M(-3433.3%) | $6.80M(-215.3%) |
| Sep 1993 | - | -$300.00K(-250.0%) | -$5.90M(-10.6%) |
| Jun 1993 | - | $200.00K(-106.5%) | -$6.60M(-13.2%) |
| Mar 1993 | - | -$3.10M(+14.8%) | -$7.60M(+11.8%) |
| Dec 1992 | -$6.80M(+83.8%) | -$2.70M(+170.0%) | -$6.80M(+65.9%) |
| Sep 1992 | - | -$1.00M(+25.0%) | -$4.10M(+32.3%) |
| Jun 1992 | - | -$800.00K(-65.2%) | -$3.10M(+34.8%) |
| Mar 1992 | - | -$2.30M | -$2.30M |
| Dec 1991 | -$3.70M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual free cash flow?
- What is the all time high annual FCF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual FCF year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly free cash flow?
- What is the all time high quarterly FCF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly FCF year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM free cash flow?
- What is the all time high TTM FCF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM FCF year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual free cash flow?
The current annual FCF of VRTX is -$978.00M
What is the all time high annual FCF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual free cash flow is $3.93B
What is Vertex Pharmaceuticals Incorporated annual FCF year-on-year change?
Over the past year, VRTX annual free cash flow has changed by -$4.26B (-129.83%)
What is Vertex Pharmaceuticals Incorporated quarterly free cash flow?
The current quarterly FCF of VRTX is $492.00M
What is the all time high quarterly FCF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly free cash flow is $1.30B
What is Vertex Pharmaceuticals Incorporated quarterly FCF year-on-year change?
Over the past year, VRTX quarterly free cash flow has changed by $0.00 (0.00%)
What is Vertex Pharmaceuticals Incorporated TTM free cash flow?
The current TTM FCF of VRTX is -$978.00M
What is the all time high TTM FCF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM free cash flow is $4.21B
What is Vertex Pharmaceuticals Incorporated TTM FCF year-on-year change?
Over the past year, VRTX TTM free cash flow has changed by $0.00 (0.00%)